主要適用的市售醫藥品比較分析:量販市場引發激烈價格競爭的專利高牆 是由出版商GBI Research在2011年08月所出版的。
這份英文市場調查報告書包含Pages: 195 價格從美金3500起跳。
本報告提供主要適用的市售醫藥品相關驗證，安全性，有效性，治療費用，以總銷售額為基礎，進行市售醫藥品比較分析，為您概述為以下內容。
第1章 目錄
第2章 主要適用的市售醫藥品比較分析:簡介
第3章 主要適用的市售醫藥品比較分析:心臟血管(CV)
第4章 主要適用的市售醫藥品比較分析:代謝性疾病
第5章 主要適用的市售醫藥品比較分析:腸胃
第6章 主要適用的市售醫藥品比較分析:肌肉骨骼
第7章 主要適用的市售醫藥品比較分析:中樞神經系統
第8章 主要適用的市售醫藥品比較分析:血液疾病
第9章 主要適用的市售醫藥品比較分析:呼吸系統
第10章 主要適用的市售醫藥品比較分析:腫瘤
- 乳癌
- 非何杰金氏淋巴瘤
- 前列腺癌
- 非小細胞肺癌(NSCLC)
第11章 主要適用的市售醫藥品比較分析:結論
第12章 主要適用的市售醫藥品比較分析:附錄
Abstract
Summary
GBI Research, the leading business intelligence provider, has released its
latest research, “Comparative Analysis of Marketed Drugs in Major Indications
- Patent Cliff to Set Off Intense Price Competition in High Volume Markets”,
which provides insights regarding the comparative analysis of marketed drugs
based on safety, efficacy, cost of therapy and total sales revenue. The report
also delves deep into the descriptions of every marketed drug, discussing
their safety, efficacy, cost of therapy and clinical studies.
The in-depth analysis of the report is based on propriety databases, primary
and secondary research and in-house analysis by GBI Research' s team of experts.
GBI Research' s analysis showed that the marketed drugs had to score highly in
terms of safety and efficacy to ensure maximum usage. Patents assisted some of
the marketed drugs in generating sales revenue devoid of competition, with
some seeking patent extensions as well to ensure additional returns. However,
patent expiries have resulted in a decline in the cost of therapy and revenue
for some of the marketed drugs.
Scope
- Major indications with sizeable market share and growth.
- Comparative analysis of major marketed drugs in each of the major
indications, in terms of safety, efficacy, cost of therapy and total sales
revenue of the drugs.
- Detailed description of the drugs, including parameters such as safety,
efficacy, cost of therapy and clinical studies.
Reasons to buy
The report will assist business development and help marketing executives to
market products and strategize new product launches, by allowing them to
- Differentiate their products from competitors in terms of safety, efficacy
and cost of therapy.
- Invest in research to achieve novelty in treatment with an acceptable
safety and efficacy profile; and obtain patents for ensuring monopoly business.
- Exploit licensing and acquisition opportunities by identifying products
that might meet their expected returns.
- Focus on the addition of new indications to the existing ones, and
different dosage forms for patient compliance.
- Develop key strategic initiatives by studying the key strategies of top
competitors.
- Build effective strategies to market their products.
- Develop market-entry and market-expansion strategies by identifying the
indications poised for strong growth.
Table of Contents
1. Table of Contents
- 1. Table of Contents
- 1.1. List of Tables
2. Comparative Analysis of Marketed Drugs in Major Indications - Introduction
- 2.1. GBI Research Report Guidance
3. Comparative Analysis of Marketed Drugs in Major Indications - Cardiovascular
- 3.1. Pulmonary Arterial Hypertension (PAH)
- 3.1.1. Comparative Analysis
- 3.1.2. Tracleer
- 3.1.3. Remodulin
- 3.1.4. Revatio
- 3.1.5. Letairis
- 3.1.6. Ventavis
- 3.1.7. Adcirca
- 3.2. Systemic Hypertension
- 3.2.1. Comparative Analysis
- 3.2.2. Diovan
- 3.2.3. Cozaar
- 3.2.4. Vasotec
- 3.2.5. Lotension
- 3.2.6. Norvasc
- 3.2.7. Plendil
- 3.2.8. Toprol-XL
- 3.2.9. Tenormin
- 3.3. Dyslipidemia
- 3.3.1. Comparative Analysis
- 3.3.2. Lipitor
- 3.3.3. Vytorin
- 3.3.4. Zetia
- 3.3.5. Trilipix
- 3.3.6. Simcor
- 3.3.7. Lescol
- 3.3.8. Livalo
- 3.3.9. Lovaza
4. Comparative Analysis of Marketed Drugs in Major Indications - Metabolic Disorders
- 4.1. Type 2 diabetes
- 4.1.1. Comparative Analysis
- 4.1.2. Actos
- 4.1.3. Avandia
- 4.1.4. Januvia
- 4.1.5. Starlix
- 4.1.6. Byetta
- 4.1.7. Lantus
- 4.1.8. Levemir
5. Comparative Analysis of Marketed Drugs in Major Indications - Gastrointestinal
- 5.1. Gastroesophageal Reflux Disease
- 5.1.1. Comparative Analysis
- 5.1.2. Protonix
- 5.1.3. Nexium
- 5.1.4. Aciphex
- 5.1.5. Prevacid
- 5.1.6. Prilosec
- 5.1.7. Tagamet
- 5.1.8. Pepcid
- 5.1.9. Zantac
- 5.1.10. Axid
6. Comparative Analysis of Marketed Drugs in Major Indications - Musculoskeletal
- 6.1. Rheumatoid Arthritis (RA)
- 6.1.1. Comparative Analysis
- 6.1.2. Enbrel
- 6.1.3. Humira
- 6.1.4. Remicade
- 6.1.5. Rituxan
- 6.1.6. Celebrex
- 6.1.7. Orencia
7. Comparative Analysis of Marketed Drugs in Major Indications - Central Nervous System
- 7.1. Schizophrenia
- 7.1.1. Comparative Analysis
- 7.1.2. Abilify
- 7.1.3. Geodon
- 7.1.4. Zyprexa
- 7.1.5. Seroquel
- 7.1.6. Invega
- 7.1.7. Invega Sustenna
- 7.1.8. Fanapt
- 7.1.9. Saphris
- 7.2. Epilepsy
- 7.2.1. Comparative Analysis
- 7.2.2. Lyrica
- 7.2.3. Gabitril
- 7.2.4. Banzel
- 7.2.5. Vimpat
- 7.2.6. Felbatol
- 7.2.7. Sabril
- 7.3. Alzheimer' s Disease
- 7.3.1. Comparative Analysis
- 7.3.2. Aricept
- 7.3.3. Exelon
- 7.3.4. Namenda
- 7.4. Parkinson' s Disease (PD)
- 7.4.1. Comparative Analysis
- 7.4.2. Stalevo
- 7.4.3. Requip XL
- 7.4.4. Azilect
- 7.4.5. Mirapex
8. Comparative Analysis of Marketed Drugs in Major Indications - Blood Disorders
- 8.1. Anemia
- 8.1.1. Comparative Analysis
- 8.1.2. Aranesp
- 8.1.3. Eprex
- 8.1.4. Venofer
- 8.1.5. Mircera
- 8.1.6. NeoRecormon
9. Comparative Analysis of Marketed Drugs in Major Indications - Respiratory
- 9.1. Asthma
- 9.1.1. Comparative Analysis
- 9.1.2. Singulair
- 9.1.3. Accolate
- 9.1.4. Zyflo
- 9.1.5. Foradil Aerolizer
- 9.1.6. Symbicort
- 9.1.7. Xolair
- 9.1.8. Serevent Diskus
- 9.1.9. Advair Diskus
- 9.2. Chronic Obstructive Pulmonary Disorder (COPD)
- 9.2.1. Comparative Analysis
- 9.2.2. Spiriva Handihaler
- 9.2.3. Brovana
- 9.2.4. Foradil Aerolizer
- 9.2.5. Symbicort
- 9.2.6. Advair Diskus
10. Comparative Analysis of Marketed Drugs in Major Indications - Oncology
- 10.1. Breast Cancer
- 10.1.1. Comparative Analysis
- 10.1.2. Abraxane
- 10.1.3. Arimidex
- 10.1.4. Femara
- 10.1.5. Herceptin
- 10.1.6. Taxotere
- 10.1.7. Xeloda
- 10.1.8. Tykerb
- 10.1.9. Avastin
- 10.2. Non-Hodgkin' s Lymphoma
- 10.2.1. Comparative Analysis
- 10.2.2. Rituxan
- 10.2.3. Velcade
- 10.2.4. Bexxar
- 10.2.5. Zevalin
- 10.2.6. Treanda
- 10.3. Prostate Cancer
- 10.3.1. Comparative Analysis
- 10.3.2. Taxotere
- 10.3.3. Casodex
- 10.3.4. Provenge
- 10.3.5. Eligard
- 10.3.6. Firmagon
- 10.3.7. Decapeptyl SR
- 10.4. Non-Small Cell Lung Cancer (NSCLC)
- 10.4.1. Comparative Analysis
- 10.4.2. Alimta
- 10.4.3. Avastin
- 10.4.4. Gemzar
- 10.4.5. Iressa
- 10.4.6. Tarceva
- 10.4.7. Taxotere
11. Comparative Analysis of Marketed Drugs in Major Indications - Conclusion
12. Comparative Analysis of Marketed Drugs in Major Indications - Appendix
- 12.1. Market Definitions
- 12.2. Abbreviations
- 12.3. Research Methodology
- 12.3.1. Coverage
- 12.3.2. Secondary Research
- 12.3.3. Primary Research
- 12.3.4. Expert Panel Validation
- 12.4. Contact Us
- 12.5. Disclaimer
- 12.6. Sources
List of Tables
- Table 1: Comparative Analysis of Marketed Drugs, Pulmonary Arterial
Hypertension, 2011
- Table 2: Comparative Analysis of Marketed Drugs, Systemic Hypertension,
2011
- Table 3: Comparative Analysis of Marketed Drugs, Systemic Hypertension,
2011
- Table 4: Comparative Analysis of Marketed Drugs, Dyslipidemia, 2011
- Table 5: Comparative Analysis of Marketed Drugs, Dyslipidemia, 2011
- Table 6: Comparative Analysis of Marketed Drugs, Type 2 diabetes, 2011
- Table 7: Comparative Analysis of Marketed Drugs, Gastroesophageal Reflux
Disease, 2011
- Table 8: Comparative Analysis of Marketed Drugs, Gastroesophageal Reflux
Disease, 2011
- Table 9: Comparative Analysis of Marketed Drugs, Rheumatoid Arthritis, 2011
- Table 10: Comparative Analysis of Marketed Drugs, Schizophrenia, 2011
- Table 11: Comparative Analysis of Marketed Drugs, Schizophrenia, 2011
- Table 12: Comparative Analysis of Marketed Drugs, Epilepsy, 2011
- Table 13: Comparative Analysis of Marketed Drugs, Alzheimer' s Disease, 2011
- Table 14: Comparative Analysis of Marketed Drugs, Parkinson' s Disease, 2011
- Table 15: Comparative Analysis of Marketed Drugs, Anemia, 2011
- Table 16: Comparative Analysis of Marketed Drugs, Asthma, 2011
- Table 17: Comparative Analysis of Marketed Drugs, Asthma, 2011
- Table 18: Comparative Analysis of Marketed Drugs, Chronic Obstructive
Pulmonary Disorder, 2011
- Table 19: Comparative Analysis of Marketed Drugs, Breast Cancer, 2011
- Table 20: Comparative Analysis of Marketed Drugs, Breast Cancer, 2011
- Table 21: Comparative Analysis of Marketed Drugs, Non-Hodgkin' s Lymphoma,
2011
- Table 22: Comparative Analysis of Marketed Drugs, Prostate Cancer, 2011
- Table 23: Comparative Analysis of Marketed Drugs, Non-Small Cell Lung
Cancer, 2011
|
